View More
Ruxolitinib plus thalidomide achieved objective disease improvements in patients with myelofibrosis in phase II study from ASH 2018 reported by Clinical Care Options (CCO).
Results from the CASSINI study of rivaroxaban for VTE prophylaxis in ambulatory patients with cancer from ASH 2018 reported by Clinical Care Options (CCO).
Results from phase I LEGEND-2 trial of LCAR-B38M CAR T-cell therapy in R/R multiple myeloma from ASH 2018 reported by Clinical Care Options (CCO).
Phase III RV-MM-PI-0752 study on optimizing lenalidomide/dexamethasone for elderly patients with newly diagnosed MM from ASH 2018 reported by Clinical Care Options (CCO).
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.
CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.